Thermosome

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. Thermosomes lead drug candidate THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG2-TSL-DOX). It has a different mode of action than conventional liposomes. Thermosomes technology enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in an up to 15-fold higher local...

Drug development,soft tissue sarcoma,thermosensitive liposome,tsl,orphan disease,oncology,cancer,biotech,tumortargeting,cancertherapy,sarcoma,cancertreatment,and clinicaltrial

Thermosome operates in the Biotechnology research industry.

Thermosome's revenue is 11m - 100m

Thermosome has 11 - 50 employees.